New developments in Sézary syndrome

Sézary syndrome (SS) represents 3% of cutaneous T-cell lymphomas (CTCL). It is an aggressive epidermotropic CTCL with a 5-year survival rate of 24%. According to EORTC (European organization for research and treatment of cancer), SS is defined by erythroderma, diffuse lymphadenopathy, atypical T lym...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annales de dermatologie et de vénéréologie 2012-01, Vol.139 (1), p.31-40
Hauptverfasser:	Caudron, A, Marie-Cardine, A, Bensussan, A, Bagot, M
Format:	Artikel
Sprache:	fre
Schlagworte:	Animals Antibodies, Monoclonal - therapeutic use Antineoplastic Agents - therapeutic use Apoptosis - drug effects Biomarkers, Tumor - analysis Combined Modality Therapy Diphtheria Toxin - therapeutic use Disease Models, Animal Electrons - therapeutic use Hematopoietic Stem Cell Transplantation Histone Deacetylase Inhibitors - therapeutic use Humans Interferon-alpha - therapeutic use Interleukin-2 - therapeutic use Mice Mice, SCID Molecular Targeted Therapy Photopheresis PUVA Therapy Receptors, KIR3DL2 - analysis Receptors, KIR3DL2 - genetics Recombinant Fusion Proteins - therapeutic use Sezary Syndrome - diagnosis Sezary Syndrome - drug therapy Sezary Syndrome - pathology Sezary Syndrome - therapy Skin Neoplasms - diagnosis Skin Neoplasms - drug therapy Skin Neoplasms - pathology Skin Neoplasms - therapy Tetrahydronaphthalenes - therapeutic use Therapies, Investigational
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!